Cell line · CVCL_0021
Papers213
2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 213
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Pharmacokinetic Tuning Redirects β‐Lapachone From NQO1 Bioactivation to Vimentin‐Targeted Oxidation in Cancer | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dactolisib outperforms Rapamycin in potentiating apoptosis induced by XPO1, Bcl-2 and Mcl-1 blockade in preclinical glioblastoma models. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Low-Density Lipoprotein Receptor-Targeted Biomimetic Nanoplatform Suppresses Glioblastoma Stemness and Remodels Antitumor Immunity via Dual Metabolic Disruption. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Genome-wide CRISPR screen identifies PKMYT1 inhibition as a synthetic lethal vulnerability in IDH1-mutant glioma. | Cancer Lett | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting LDHA Palmitoylation Sensitizes GBM to Chemoradiotherapy via Suppressing Palmitic Acid Induced Glycolytic Reprogramming. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PLOD1 Catalytic Activity Stabilizes ENO1 by Limiting FBXW7-dependent Degradation to Promote Glycolysis and TMZ Resistance in Glioblastoma. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CCND1 Stability Regulated by USP7 Deubiquitination Controls Glioma Radioresistance via Ferroptosis. | Anal Cell Pathol (Amst) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TIMELESS promotes glioma stemness and malignancy through JAK-STAT3 pathway. | J Biol Chem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| COPS7B Drives Malignant Progression of Glioblastoma Through Translational Upregulation of the Downstream Functional Effector CLU. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Systematic Targeting of Protein Complexes with Molecular COUPLrs. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Uncovering MYOF as a novel therapeutic target in glioblastoma: mechanistic insights and drug discovery. | Cell Death Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Framework for evaluating in vitro vasculogenic mimicry using structural and metabolic parameters. | Cell Rep Methods | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TAF15-mediated m5C modification of MTHFD2 RNA reveals a novel therapeutic target for IDH mutant gliomas. | Biomark Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Notch Overexpression Potentiates Interferon Signaling in Glioma Cells. | Curr Issues Mol Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Exosomal circ_0050688 Shapes a Chemoresistant Microenvironment by Driving Spatial Resistance Spreading in Glioblastoma via the MDM2 Pathway. | Biomolecules | 2026 | Its Methods give the RRID and name the line | PubMed | |
| B7 homolog 3-targeted CAR-T cells secreting EGFR T-cell engagers for improved control of glioblastoma progression. | Mol Biomed | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Pharmacological Ascorbate Restrains Epithelial-Mesenchymal Transition and Invasion in Glioblastoma Cells via Extracellular H2O2 Generation. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A novel oncolytic herpes simplex virus type 2 induces polarization of tumor-associated macrophages and remodels the immune microenvironment in glioblastoma. | Cancer Immunol Immunother | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose-driven glioblastoma. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0021/papers